Advertisement
The KEYNOTE-590 phase III trial aimed to evaluate 5-yr survival for 1L pembro + chemo vs. pbo + chemo in advanced esophageal cancer patients. The primary endpoints were OS in ESCC with PD-L1 CPS ≥10 and OS/PFS per RECIST v1.1 in all ESCC patients. The results demonstrated lasting effectiveness without new safety issues […]...
Advertisement
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated with BTEs. Methods Leveraging the US …
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …
With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the development of innovative treatment strategies is increasingly vital. This review underscores the pivotal role of precision medicine in transforming NSCLC management, …
Introduction: Spinal metastases are common in metastatic cancer, affecting around 40% of patients. The primary treatment involves radiation therapy, transitioning from conventional external beam radiation therapy (EBRT) to stereotactic body radiation therapy (SBRT) for its …
